[1] Nasser NJ, Fox J, Agbarya A. Potential mechanisms of cancer-related hypercoagulability[J]. Cancers (Basel), 2020, 12(3): 566.
[2] Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism[J]. Nat Rev Dis Primers, 2022, 8(1): 11.
[3] Falanga A, Russo L, Milesi V, et al. Mechanisms and risk factors of thrombosis in cancer[J]. Crit Rev Oncol Hematol, 2017, 118: 79-83.
[4] 王砚春, 卢仁泉. 出凝血检测在肿瘤患者中的应用价值探讨[J]. 诊断学理论与实践, 2023, 22(4): 341-347.
[5] Akinbo DB, Ajayi OI. Thrombotic pathogenesis and laboratory diagnosis in cancer patients, an update[J]. Int J Gen Med, 2023, 16: 259-272.
[6] Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis[J]. Transl Res, 2020, 225: 33-53.
[7] Hisada Y, Mackman N. Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and survival[J]. Curr Opin Hematol, 2019, 26(5): 349-356.
[8] Abdol Razak NB, Jones G, Bhandari M, et al. Cancer-associated thrombosis:an overview of mechanisms, risk factors, and treatment[J]. Cancers (Basel), 2018, 10(10): 380.
[9] van der Pol E, Welsh JA, Nieuwland R. Minimum information to report about a flow cytometry experiment on extracellular vesicles: communication from the ISTH SSC subcommittee on vascular biology[J]. J Thromb Haemost, 2022, 20(1): 245-251.
[10] Urano T, Suzuki Y, Iwaki T, et al. Recognition of plasminogen activator inhibitor type 1 as the primary regulator of fibrinolysis[J]. Curr Drug Targets. 2019, 20(16): 1695-1701.
[11] Koizume S, Miyagi Y. Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications[J]. Br J Cancer, 2022 , 127(12): 2099-2107.
[12] Pavlovic D, Niciforovic D, Markovic M, et al. Cancer-associated thrombosis:epidemiology, pathophysiological mechanisms, treatment, and risk assessment[J]. Clin Med Insights Oncol, 2023, 17: 11795549231220297.
[13] Pastori D, Cormaci VM, Marucci S, et al. A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology[J]. Int J Mol Sci, 2023, 24(4): 3169.
[14] Oli AN, Adejumo SA, Rowaiye AB, et al. Tumour immunotherapy and applications of immunological products: a review of literature[J]. J Immunol Res, 2024, 2024: 8481761.
[15] Shields LBE, Daniels MW, et al. Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy[J]. World J Clin Oncol, 2021, 12(3): 183-194.
[16] Patel H, Sun H, Hussain AN, et al. Advances in the diagnosis of venous thromboembolism:a literature review[J]. Diagnostics (Basel), 2020, 10(6):365.
[17] Anghel L, Sascău R, Radu R, et al. From classical laboratory parameters to novel biomarkers for the diagnosis of venous thrombosis[J]. Int J Mol Sci, 2020, 21(6): 1920.
[18] Lu T, Yan H, Luo J, et al. Elevated thrombosis-related biomarkers as predictors of disease severity and mortality in patients with severe fever withthrombocytopenia syndrome[J]. BMC Infect Dis, 2025, 25(1): 235.
[19] Yagi K, Tao Y, Hara K, et al. Increased plasma plasmin-α2-plasmin inhibitor complex levels correlate with postoperative rebleeding after endoscopic surgery for spontaneous intracerebral hemorrhage[J]. Acta Neurochir (Wien), 2020, 162(12): 3129-3136.
[20] Zhao X, Yang S, Lei R, et al. Value of novel thrombotic markers for predicting occurrence of the malignant cerebral artery infarction: a prospective clinical study[J]. Front Neurol, 2023, 14: 1238742.
[21] Huang L, Deng X, Fan RZ, et al. Coagulation and fibrinolytic markers offer utility when distinguishing between benign and malignant gallbladder tumors: A cross-sectional study[J]. Clin Chim Acta, 2024, 560: 119751.
[22] Mei H, Jiang Y, Luo L, et al. Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation: a multi-center prospective observational study[J]. Thromb Res, 2019, 173: 20-26.
[23] Zhou K, Zhang J, Zheng ZR, et al. Diagnostic and prognostic value of tat, pic, tm, and t-paic in malignant tumor patients with venous thrombosis[J]. Clin Appl Thromb Hemost, 2020, 26: 1076029620971041.
[24] 张青, 冯鹭, 于超, 等. 肺癌患者血栓四项标志物检测的临床意义[J]. 临床检验杂志, 2019, 37(11): 4.
[25] Gong F, Zheng X, Zhao S, et al. Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy[J]. Med Comm (2020), 2025, 6(2): e70058.
[26] Yu N, Shi M, Li H, et al. Peripheral blood plasminogen activator inhibitor 1 and tissue-type plasminogen activator-inhibitor complex levels for the diagnosis and prediction value of venous thromboembolism in malignant tumors[J]. Arch Pathol Lab Med, 2025, 149(11): e329-e338.
[27] Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study[J]. Thromb Res, 2010, 125(3): e65-70.
[28] Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 Trial[J]. J Clin Oncol, 2015, 33(18): 2028-2034.
